Biomecite Diagnostics is a development-stage medical diagnostics company
Biomecite Diagnostics is commercializing a diagnostic platform based on a microbiome signature technology developed at the University of Maryland, Baltimore. This diagnostic tool explores distinct variances in the DNA of the populations of all bacteria or the “microbiome” found in the human gut to diagnose patients suffering from various diseases.
Biomecite IBD Diagnostic
Biomecite’s first diagnostic target is Inflammatory Bowel Disease (IBD). The Biomecite diagnostic will be used primarily by Primary Care Physicians to differentiate patients with Irritable Bowel Syndrome (IBS) from IBD quickly, allowing earlier therapeutic intervention. Symptoms of these diseases are similar and typically require five doctor visits before referrals are made to specialists for diagnosis. IBS affects up to 45 million people in the US and up to 40% of GI visits are due to IBS symptoms (aboutibs.org). The Biomecite diagnostic will provide accurate diagnosis in a week, with one simple at home stool collection.
The tool relies on the analysis of signature genetic sequences obtained directly from patient stool samples.
This state-of-the-art technology belongs to the rapidly expanding field of microbiome-based diagnostics.
HELPING IBD PATIENTS
The Gastriome Test will be available without discomfort or risk to the patient at a cost effective price and could potentially help tens of millions of patients worldwide.
PROOF OF CONCEPT STUDY
Biomecite Diagnostics is currently conducting a 90 patient proof of concept study.